Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Baxter International ( (BAX) ) has shared an update.
On December 4, 2025, Baxter International Inc. announced the issuance of $2 billion in senior notes, with proceeds intended to fund a tender offer for its 2026 and 2027 notes. The company reported early tender results and pricing for these offers, indicating a strong investor response, which may enhance its financial flexibility and strategic positioning.
The most recent analyst rating on (BAX) stock is a Sell with a $15.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including high leverage and negative profitability, which are reflected in its valuation metrics. Technical indicators suggest a bearish trend, further weighing on the stock’s outlook. While the earnings call provides some positive guidance, the overall risks and challenges overshadow potential growth opportunities.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. is a global healthcare company providing essential solutions in hospitals, physician offices, and other care sites. With a nearly century-long history, Baxter is known for its connected solutions, medical devices, and advanced injectable technologies, employing approximately 38,000 team members dedicated to saving and sustaining lives.
Average Trading Volume: 7,265,320
Technical Sentiment Signal: Sell
Current Market Cap: $9.68B
For detailed information about BAX stock, go to TipRanks’ Stock Analysis page.